Clinical Observation Of The Therapeutic Outcome With Combiantion Of Arenic Trioxide And LPA Regimen In Newly Diagnosed Actute Promyelocytic Leukemia

Objective:To explore the therapeutic outcome and side effect of patients with acutepromyelocytic leukemia(APL) treated with Arsenic trioxide (ATO) and LPA regimen.Methods:13 newly diagnosed APL patients were treated with ATO and AIDA regimen asinduction therapy followed by 3 courses of consolidation therapy combined ATRA withchemotherapy and 2 year maintenance therapy with ATO and ATRA+6-MP+MTX,alternatively. Patients were regularly monitored with nested RT-PCR for PML-RARαfusiongene at the end of consolidation chemotherapy.Results:A total of 13 patients with APL were entered the regimen, 13(100%) patients allachieved complete remission(CR). Early death rate was 0%. Of 10 patients(90%)receivedconsolidation, all of them were proved PML-RARαfusion gene negative at the end of the 3rdcourses. The other three cases, one case was lost after cessation of treatment, two case is stillunder consolidation therapy. The mean follow-up was 18(2-32)months, there was no relapsedpatient(0%) observed. The common side effect were myelosuppression, secondary infectionand hemorrhage , hepatic impairment, but no influenced subsequent treatment.Conclusion:Arsenic trioxide combined with LPA regimen is an effective and safety treatmentfor patients with acute promyelocytic leukemia, and there is less adverse events in patients.